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Abstract
The role of the species Mycobacterium haemophilum as a pathogenic non-tuberculous microorganism is becoming better deﬁned with the
use of speciﬁc detection methods. However, epidemiological investigations of this species are still scarce. We analysed the genetic
diversity of M. haemophilum by ampliﬁed fragment length polymorphism (AFLP) typing and compared isolates from different parts of the
world. In total, 128 isolates, including 41 from the USA, 51 from Australia, 28 from Europe and eight from Israel were compared using
AFLP methodology. Two restriction enzymes (MseI and EcoRI) and one selective primer were applied and provided a high discrimina-
tory power. Clusters of isolates with identical AFLP patterns, which could indicate a possible common source, were observed from the
Netherlands, New York and Australia. No clear clustering on the basis of continental origin was observed; however, types were
restricted to geographical areas and not found on other continents. A high genetic stability within the species was demonstrated by the
long-term existence of a single type.
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Introduction
Mycobacterium haemophilum was ﬁrst described in 1978
following isolation from the cutaneous lesions of a woman
with Hodgkin’s disease [1]. The organism is unusual in that it
has an optimal temperature for in vitro growth in the range
30–32C, and a requirement for supplementation of growth
media with iron-containing compounds, such as ferric ammo-
nium citrate or haemin. Mycobacterium haemophilum most
often causes joint, cutaneous and pulmonary infections in
immunocompromised patients and lymphadenitis in immuno-
competent children, although infections in immunocompetent
adults do occur [2,3]. In recent studies, M. haemophilum was
identiﬁed as the second most common mycobacterial patho-
gen causing cervicofacial lymphadenitis in children in the
Netherlands [4,5]. There is no evidence of patient-to-patient
spread of the organism and M. haemophilum infections appear
to be acquired from the environment, most likely from water
and bioﬁlms [6–8]. Clusters of cases representing a variety of
clinical manifestations from Australia [9], Israel [10], New
York [11] and the Netherlands [4] have been reported.
Molecular epidemiology studies have suggested clonal geo-
graphical clustering [12,13]. To analyse the molecular related-
ness and global diversity of M. haemophilum, isolates from
Australia, Europe, Israel and the USA were typed by ampliﬁed
fragment length polymorphism (AFLP). The AFLP method is
based on the selective ampliﬁcation of genomic fragments,
after digestion by one or more restriction enzymes, and visu-
alization of band patterns. The genomic mutations that cause
a restriction site to emerge or disappear, or that change the
length of the fragment between the restriction sites, give rise
to differences in band patterns [14].
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Compared to pulse ﬁeld gel electrophoresis (PFGE), as
a gold standard for typing, AFLP has been shown to be as
discriminative, or even more discriminative, for certain
mycobacteria [15,16].
Materials and methods
Mycobacterial isolates
Isolates of M. haemophilum were obtained from the following
centres: Leiden University Medical Center, Leiden, the Neth-
erlands; Memorial Sloan-Kettering Cancer Center, New
York, NY, USA; Western Australian Centre for Pathology &
Medical Research, Nedlands WA, Australia; Rabin Medical
Center, Petach-Tiqva, Israel; Institute of Microbiology,
University of Oslo, Oslo, Norway; and the Laboratory for
Microbiology and Virology, Ospedale Careggi, Firenze, Italy.
Isolates were shipped either freeze-dried or as a culture,
and, upon arrival in Leiden, were cultured on Lo¨wenstein–
Jensen medium with added ferric ammonium citrate and
incubated at 30C. Other mycobacterial species were
cultured on Lo¨wenstein-Jensen medium with added poly-
myxin B, amphotericin B, carbenicillin, and trimethoprim and
incubated at 35C (Becton Dickinson, Alphen a/d Rijn, the
Netherlands). After sufﬁcient growth, aliquots of the organ-
isms were stored at )20C pending DNA extraction. In
total, 182 M. haemophilum isolates were collected of which
54 failed to grow. The remaining 128 M. haemophilum
isolates (including two tested in duplicate) were subjected to
genotyping and are described in Table 1.
Seven mycobacterial species, including M. haemophilum,
were tested for species differentiation by the AFLP protocol.
Closely-related species to M. haemophilum, based on com-
bined phylogenetic analysis of different genomic targets, were
Mycobacterium malmoense and Mycobacterium heidelbergense
[17]. Species that appeared closely related based on only 16S
rRNA gene phylogeny were Mycobacterium szulgai and Myco-
bacterium bohemicum [18,19]. Mycobacterial species with less
phylogenetic closeness to M. haemophilum were Mycobacte-
rium interjectum and one unidentiﬁed species, OMS011. All of
these strains were clinical isolates from the Leiden University
Medical Center collection or provided by the National
Tuberculosis Reference Center (RIVM) and all were identi-
ﬁed by the RIVM by 16S rRNA gene sequencing [20].
AFLP procedure optimization
Optimization of AFLP involved two procedures. (i) Differ-
ent methods of DNA extraction: QIAamp DNA mini kit
(Qiagen Benelux, Venlo, the Netherlands), MoBio Ultra-
clean Microbial DNA isolation Kit (Sanbio, Uden, the
Netherlands), ZR Genomic DNA kit and DNA II kit
(Zymo Research, Orange, CA, USA) and the Boom extrac-
tion method [21]. All DNA extraction methods were
tested according to the manufacturers’ protocols, with or
without sonication and proteinase pre-steps. (ii) Variations
in the AFLP protocol: incubation time and cycling condi-
tions. Strains were re-cultured several times to provide
fresh isolates for the different trials during the optimiza-
tion process. During optimization of the typing procedure,
DNA extraction was performed in triplicate.
DNA extraction
For DNA extraction, one or more colonies were suspended
in molecular grade water and sonicated three times for 5 s
at 8 microns (amplitude) prior to an overnight incubation
with proteinase K (2 mg/mL) at 50C (Invitrogen, Breda, the
Netherlands). DNA was extracted using the MoBio Ultra-
clean Microbial DNA isolation Kit (Sanbio) and eluted in
100 lL (50 lL of elution buffer with 50 lL of molecular
grade water). The ﬁnal concentration and purity of the DNA
was conﬁrmed with the Nanodrop ND 1000 (Nanodrop
Technologies, Wilmington, DE, USA) and, for successful
patterns, a concentration in the range 5–20 ng/lL (5 lL/
reaction) and a purity optical density in the range 1.50–2.30
(260/280 coefﬁcient) were used.
TABLE 1. Clinical isolates of Mycobacterium haemophilum
Country or
continent
Number
of strains
Year of
isolation
AFLP types
(no. of isolates)
AFLP type
variants
included
USA 41 1991–2001 USA A (29) 4
1990–1991 USA B (5)
1998 USA C (1)
1991–1993 USA D (3)
2000 USA E (2)
1984 USA F (1)
Israel 8 1996–2003 East A (2) 1
2003 East B (1)
1971 East C (1)
2003 East D (1)
2003–2004 East E (2) 1
1996 East F (1)
Australia 51 1987–2003 Aus A (23) 3
1987 Aus B (1)
1986–2004 Aus C (16)
1990–1996 Aus D (2)
2003 Aus E (1)
2004 Aus F (1)
2000 Aus G (1)
1977 Aus H (1)
Unknown Aus I (1)
Unknown Aus J (1)
Unknown Aus K (1)
Unknown Aus L (2)
Europe 28 2003–2005 Eur A (24) 1
2004 Eur B (1)
2004 Eur C (1)
2003 Eur D (1)
2000 Eur E (1)
AFLP, ampliﬁed fragment length polymorphism.
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Genotyping
The AFLP procedure comprised: 3 h at 37C (digestion and
simultaneous ligation of the adaptors). The restriction/ligation
mix contained 10 · T4-ligation buffer (Westburg, Leusden,
the Netherlands), 0.5 M NaCl, 0.5 lg of bovine serum albu-
min (Westburg), 2 pmol EcoRI adaptor (Eurogentec,
Maastricht, the Netherlands), 20 pmol MseI adaptor
(Eurogentec), 80 U of T4-ligase (Westburg), 1 U of MseI
(Westburg) and 1 U of EcoRI (Westburg) in a 5-lL volume
per reaction and 5 lL of DNA. Subsequently, the restriction/
ligation product mixture was diluted 20-fold in 0.1x. Tris-
EDTA-buffer before ampliﬁcation. PCR was carried out in
10 · PCR buffer (Applied Biosystems, Foster City, CA, USA),
15 nmol MgCl2, 2 nmol DNTPs, 20 ng of primer Eco-0
(5¢-GACTGCGTACCAATTC-3¢) (Applied Biosystems), 60 ng
of primer Mse-C (5¢-GATGAGTCCTGAGTAAC-3¢) (Euro-
gentec) and 1 U of Ampli-taq polymerase (Applied
Biosystems). Five microlitres of PCR mix was added to 5 lL
of diluted restriction/ligation product mixture. The PCR pro-
gram started with an activation of 2 min at 72C, 35 cycles
with a touchdown principle: 30 s at 94C, 10 s at 65–56C,
1 min at 72C (annealing ﬁrst cycle at 65C, 12 cycles of 0.7
degrees down per cycle, followed by 23 cycles at 56C), and
a ﬁnal extension of 10 min at 72C. A sample of 2.5 lL of
PCR product was added directly in 22.5 lL of HiDi formam-
ide (Applied Biosystems) with ROX500 (Applied Biosystems)
as internal marker and analysed in an ABI3100 genetic analy-
ser (Applied Biosystems).
Analysing patterns
AFLP patterns were analysed and calculations were performed
with the Bionumerics software (Applied Maths, Sint-Martens-
Latem, Belgium). During optimization of the protocol, the AFLP
patterns (PCR fragments length distribution) were analysed
with Pearson’s coefﬁcient and the unweighted pair group
method with mathematical averaging (UPGMA) cluster analysis.
Application of Pearson’s coefﬁcient resulted in intensity differ-
ences of bands that affected the similarity calculations for
strains with identical and highly similar band patterns. There-
fore, another approach was chosen for the study of the M. hae-
mophilum collection. Digitized bands were assigned to the AFLP
fragments and the Dice coefﬁcient and UPGMA cluster analysis
were applied to the band patterns. For a subset of threeM. hae-
mophilum strains, Pearson analysis was compared with Dice
analysis (Fig. 2a,b). To exclude subjective interpretation, dupli-
cate AFLP reactions were included from each isolate in the
M. haemophilum collection. The average number of bands per
pattern was 50. Bands of between 85 and 350 nucleotides were
included in the analysis. A strain was considered different from
another when at least one band was different in the Dice pat-
tern because one band difference is associated with a detect-
able mutational event [22]. One band difference was designated
a ‘variant type’, whereas a difference of two or more bands
was considered to deﬁne a ‘type’. Designation of types was
carried out by continent of origin and does not imply informa-
tion concerning the genetic difference or similarity (e.g. type-
designation USA A has no correlation with designation Aus A).
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FIG. 1. AFLP patterns of different species in triplicate, calculation with Pearson’s coefﬁcient. Mycobacterium sp. is the unidentiﬁed species
OMS011, which clearly does not belong to one of the species included in the analysis. The similarity between different species is well below
15%, including the standard deviation.
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Results
Optimization of the molecular typing procedure
The optimization process utilized the method described in
the Materials and methods. A panel of strains was used to
validate the different levels of discrimination. Seven different
species, including M. haemophilum (strain Netherlands 5),
were tested in triplicate and compared (Fig. 1). All patterns
were calculated with Pearson’s coefﬁcient. The similarity
between species was well below 15% with this AFLP proto-
col. Therefore, the applied method was clearly capable of
discriminating different mycobacterial species. The pattern
homology between different DNA extracts of the same
strain was 90% or more when calculations were made with
Pearson’s coefﬁcient (Fig. 2a). The variability between these
DNA extracts after assignment of digitized bands for Dice
calculation showed a similarity of 100% (Fig. 2b).
Molecular typing
The AFLP procedure (including Dice analysis) was used for
typing 128 clinical isolates of M. haemophilum representing
four geographical areas: eight were from Israel, 41 from the
USA, 28 from Europe and 51 from Australia (Table 1).
Pattern comparisons of 122 of the collection of 128
M. haemophilum isolates are provided in the Supporting infor-
mation (Figure S1); those excluded showed equivalent pat-
terns to those of the included isolates. The lowest similarity
between strain pairs was 78%. No clear overall clustering
based on continental origin was observed. All types were
unique to their continent of origin and not found in other
continents. However, the types from each continent were
not necessarily the most similar to each other. For example,
type USA A was conﬁned to a cluster among the New York
isolates, but other USA types fell into other clusters in the
dendrogram. Only one band difference was observed
between types Eur A and Aus A, and they are therefore con-
sidered to be variant strains of the same type.
Among the 41 isolates from the USA; 38 were from seven
New York hospitals (1989–2001), two were from Seattle
(2000) and two were from Phoenix (1984). All of the
patients except one were adults, and most had AIDS or
cancer and/or were transplant patients. There were six AFLP
types (USA A–F). USA A, including a type variant, was the
most prevalent type (29 isolates) and was only found in New
York hospitals. Among the New York isolates, 15 were from
patients at one hospital. Type USA B was found in four
patients at two New York hospitals, and all four patients
possibly acquired the infection outside New York, in the late
1980s (according to their physicians). Type USA C was
isolated from a lung nodule from a patient at a New York
hospital, but the immunocompetent patient probably
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FIG. 2. Ampliﬁed fragment length polymorphism patterns of three Mycobacterium haemophilum strains in triplicate. Calculations with (a) Pearson’s
coefﬁcient and (b) Dice calculation.
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acquired the infection when at home in the Philippines [23].
Type USA D was only found in three AIDS patients at one
New York hospital, early in the 1990s. Type USA E was iso-
lated from two patients at a hospital in Seattle, one patient
with AIDS and the other with diabetes, in 2000. Type USA F
was isolated from a renal transplant patient in Phoenix, in
1984.
Of the eight isolates from Israel, seven were obtained
from lymph node specimens between 1996 and 2003 and the
other represented the ﬁrst known isolate of M. haemophilum
(ATCC 29548), from 1971. The ATCC strain from Israel
clustered with other isolates from Israel (94%), but identical
patterns were not observed. The eight isolates could be
divided into two clusters of which one cluster forms the
most distinct cluster of strains in this collection, showing
77% similarity with all others.
Within the collection of 51 isolates from Australia, two
large type clusters of identical patterns, Aus A and Aus C,
and 12 isolates representing ten other types could be recog-
nized. Type Aus A consisted of 23 isolates, including three
with type Aus A var, a type that remained unchanged from
1987 through 2002. The type Aus C included 16 isolates and
remained unchanged from 1986 through 2004. The minimum
similarity between the other Australian types, Aus B and Aus
D–L, was 85% and they appear to be scattered throughout
the dendrogram. Approximately half of the Australian iso-
lates were from immunocompromised patients and isolates
were recovered from various sites.
The European collection of 28 isolates consisted of 26
from the Netherlands, of which 22 were from the
Amsterdam region and four from other regions of the
Netherlands, one from Norway and one from Italy. Twenty-
three Netherlands isolates typed as Eur A of which 21 were
from the Amsterdam region and all were from children with
cervicofacial lymphadenitis. The Norwegian isolate differed
in only one band from the Amsterdam type and is there-
fore designated type Eur A var. Four other types, Eur B–E,
were identiﬁed once for each type of which one (Eur B)
was from the Amsterdam region and one (Eur E) was from
Italy.
Discussion
Molecular methods play an increasingly important role in our
investigation of epidemiological strain characteristics and the
signiﬁcance to patients of infectious microorganisms.
Although several species of mycobacteria have been exam-
ined extensively by molecular methods, there is very limited
information about the diversity of M. haemophilum. Previ-
ously, two molecular methods, a restriction fragment length
polymorphism (RFLP) assay [12] and a PFGE assay [13], have
been used to type USA isolates of M. haemophilum, mostly
from the New York area. These two studies demonstrated
genetic clustering within the tested strain collections, which
could indicate a common source. The RFLP showed similar
discriminatory power to the PFGE [12,13]. We used AFLP
to type 15 isolates previously typed by RFLP in New York in
1994 and found that ﬁve different RFLP types corresponded
with ﬁve different AFLP types (data not shown) [12]. There-
fore, the discriminatory power of all three methods appears
to be similar.
The main objective of the present study was to investigate
the level of genetic diversity among isolates of M. haemophilum
collected from several parts of the world and typed by AFLP.
Prior to comparing the different isolates of M. haemophilum,
we conducted a validation procedure to obtain the opti-
mal discriminatory power of the AFLP method for
M. haemophilum at the strain and species level. The enzyme
combination with one selective primer showed a suitable
fragment distribution for this species. Because M. haemophilum
has a strong tendency to clump, a stringent protocol was nec-
essary to obtain DNA of high quality and in sufﬁcient quanti-
ties from bacterial colonies. A combination of sonication and
enzymatic and mechanical disruption resulted in pure DNA
and subsequently reproducible AFLP patterns. Although Pear-
son’s analogue analysis of the AFLP patterns revealed similar
clustering, Dice analysis enabled a clearer visualization of the
true differential patterns of a large panel of M. haemophilum
isolates. Among the 128 isolates typed in the present study,
there were indications of clustering. Isolates from the
Amsterdam region (Netherlands 1–21) produced one identi-
cal AFLP pattern, type Eur A, whereas the patterns from
isolates from other regions of the country varied, thus con-
ﬁrming the epidemiological relatedness of the Amsterdam
isolates. Most isolates from the New York area yielded an
identical pattern as well, namely type USA A, which was
observed from 1989 to 2000. Among Australian isolates, two
clusters were observed. One of these clusters remained
unchanged for 18 years (type Aus C) and the other remained
unchanged for 15 years (Aus A), suggesting an extremely low
evolutionary rate for this mycobacterium, and perhaps the
ability of the organism to persist in the environment. Previ-
ously, the persistence of the species Mycobacterium avium has
been demonstrated in water distribution systems, and this
illustrates the ability of mycobacteria to continue for a long
time in a stable niche [24]. A similar water source for M. hae-
mophilum might exist.
The difference between types is relatively high (minimal
similarity of 78%). The types Aus A and Eur A are variants
928 Clinical Microbiology and Infection, Volume 15 Number 10, October 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 924–930
with one band difference, suggesting an evolutionary link
between these two types. Type Aus A appears common in
immunocompetent patients (p <0.001) and this could indi-
cate differences in virulence between types. The 51 isolates
from Australia, in contrast to the isolates from other conti-
nents, were equally distributed among immunocompetent
patients and those with impairment of immunity. Of 23 type
Aus A and type Aus A variant isolates, 19 (83%) were
isolated from immunocompetent patients, whereas only four
isolates from immunocompetent patients were of another
type. In addition, type Eur A was solely found in immuno-
competent children. No background information is available
for the Norwegian isolate of the type Eur A variant. Two
Netherlands isolates of other types (type Eur C and type
Eur D) had both been obtained from the only two Nether-
lands patients with immune compromising conditions (data
not shown).
It is difﬁcult to deﬁne the exact origin of a strain encoun-
tered in clinical practice. In some cases, the incubation per-
iod for the infections is most likely extensive, and the
history obtained may lack information about travel, exposure
to healthcare institutions, etc. For example, among the
Australian isolates, two large clusters of similar strains have
been deﬁned, of which a few isolates have been encountered
in geographically distant locations from the rest. A common
source or geographical linkage to type distribution cannot be
excluded. The source and spread of M. haemophilum infec-
tions is still open to question. It has been difﬁcult to recover
the organism from the environment, although the scant liter-
ature suggests a water and/or bioﬁlm source [6,8]. The pres-
ent study and the studies conducted in New York suggest a
clustering of cases both by geography, patient types, clinical
presentations and time period. For example, the infections in
New York began, rather abruptly, in 1990, and were mostly
found in immunocompromised adults, particularly those with
AIDS or in individuals who had received bone marrow
transplants. The diagnostic methods in New York had not
been adjusted prior to this abrupt rise of M. haemophilum
isolates. Investigators of the M. haemophilum infections in the
Amsterdam region suggested a public indoor swimming pool
or home water supplies as possible sources of the infection.
The home water supply of one child with lymphadenitis was
examined for the presence of M. haemophilum, but real-time
PCR and culturing methods yielded only the species
Mycobacterium kansasii. That investigation was performed
several months after onset of the disease and the home
water supply can therefore not be excluded as an infection
source.
As the reported cases of M. haemophilum increase, addi-
tional epidemiological information will become available, and
we now have the molecular tools to further deﬁne the global
diversity of this organism.
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